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Abstract: Systemic sclerosis (SSc) is a connective tissue disease of unknown etiology. A hallmark of SSc is fibrosis of 
the skin and internal organs. We recently demonstrated increased expression of IGFBP-3 and IGFBP-5 in primary cultures 
of fibroblasts from the skin of patients with SSc. In vitro, IGFBP-3 and IGFBP-5 induced a fibrotic phenotype and 
IGFBP-5 triggered dermal fibrosis in mice. To assess the ability of IGFBPs to trigger fibrosis, we used an ex vivo human 
skin organ culture model. Our findings demonstrate that IGFBP-3 and IGFBP-5, but not IGFBP-4, increase dermal and 
collagen bundle thickness in human skin explants, resulting in substantial dermal fibrosis and thickening. These fibrotic 
effects were sustained for at least two weeks. Our findings demonstrate that human skin ex vivo is an appropriate model to 
assess the effects of fibrosis-inducing factors such as IGFBPs, and for evaluating the efficacy of inhibitors/therapies to 
halt the progression of fibrosis and potentially reverse it. 
INTRODUCTION 
  Systemic sclerosis (SSc) is a connective tissue disease 
whose hallmarks include fibrosis, immune dysregulation, 
and vascular abnormalities. Dermal fibrosis is a prominent 
feature of SSc. The most commonly used mouse models of 
SSc are those arising from genetic mutations or treatment 
with bleomycin [1]. Although these murine models have 
proven to be useful for understanding the role of various 
factors in fibrosis, the ultimate goal of our research is to de-
termine the applicability of our findings in humans who are 
afflicted with the disease. Furthermore, comparative studies 
have revealed important anatomical cellular and functional 
differences between human and mouse skin [2]. 
  Using human skin as an ex vivo organ model of fibrosis 
has several advantages. First, the skin explants remain viable 
in culture for at least two weeks. Second, factors and vectors 
can be readily administered to skin explants via deep and/or 
superficial injections to affect both the epidermis and dermis 
or mainly the dermis as these epidermal-dermal explants 
consist of both epidermis and dermis. Furthermore, skin ex-
plants contain all cell types resident in the skin which are 
capable of exerting their physiological effects on the tissue 
and neighboring cells. Skin explants have been successfully 
used to express transgenes in both the epidermal and dermal 
layers for vaccination and immunotherapeutic purposes [3-
6]. 
  Insulin-like growth factor binding proteins (IGFBPs) are 
a family of six proteins identified for their ability to bind 
IGF-I with high affinity [7, 8]. We have previously shown 
that IGFBP-5 is over-expressed in fibrotic lung and skin tis-
sues in patients with SSc and in lung tissues of patients with 
idiopathic pulmonary fibrosis [9-11]. We have also demon-
strated that IGFBP-5 can induce the development of a   
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fibrotic phenotype in vitro in primary fibroblasts and can 
trigger dermal and pulmonary fibrosis in vivo in murine 
models [11, 12]. Since our original observation of increased 
IGFBP-5 levels was made in human samples and the final 
goal of our studies is the applicability of our findings in hu-
mans, we optimized use of an ‘ex vivo’ organ culture model 
using human skin. The effect of IGFBP-5 on the develop-
ment of a fibrotic phenotype was examined in this ex vivo
skin explant model. Our findings suggest that expressing 
IGFBP-5, and to a lesser extent IGFBP-3, in normal skin 
explants results in increased dermal thickness and increased 
collagen bundle thickness, thus recapitulating the dermal 
fibrosis seen in patients with SSc. 
MATERIALS AND METHODOLOGY 
 Human  Samples:  Human skin was obtained from cor-
rective plastic surgery. All tissues were obtained according 
to the guidelines of the University of Pittsburgh and under a 
protocol approved by the Institutional Review Board of the 
University of Pittsburgh. Subcutaneous fat tissue was re-
moved and skin tissue was cut into 1.5 cm x 1.5 cm sections. 
Adenoviral (Ad) constructs were injected intradermally in a 
volume of 100 l 1x PBS. Explants containing complete 
epidermal and dermal layers were cultured in an air liquid 
interface with the epidermal and keratin layers side up and 
exposed to air. The culture medium was replaced daily and 
consisted of Dulbecco’s modified Eagle’s medium (DMEM) 
(Mediatech, Herndon, VA) supplemented with 10% FBS 
(Sigma-Aldrich, St Louis, MO), penicillin, streptomycin, and 
anti-mycotic agent (Invitrogen Life Technologies, Carlsbad, 
CA). At the indicated time points, skin tissue was harvested 
and fixed in 10% formalin prior to embedding in paraffin. 
Skin punch biopsies were obtained from the clinically af-
fected and unaffected skin of patients with SSc as we have 
previously described [9, 11]. 
 Adenoviral  Constructs:  Replication deficient adenovi-
ruses serotype 5 encoding human IGFBP-3, IGFBP-4, or 
IGFBP-5 were generated as previously described [10]. Ade-
novirus serotype 5 lacking cDNA was used as a control. 18    The Open Rheumatology Journal, 2008, Volume 2  Yasuoka et al. 
Adenoviruses (1 x 10
8 pfu) were injected intradermally in a 
100 l volume. 
 Immunohistochemistry  (IHC):  Six m sections of par-
affin embedded tissues were deparaffinized and endogenous 
peroxidases were quenched with 3% H2O2. Sections were 
blocked with 5% serum and incubated with polyclonal anti-
IGFBP-5 antibody (Gropep Ltd, Adelaide, Australia) or IgG 
control antibody (Lab Vision Corporation, Fremont, CA). 
Sections were washed and incubated with biontinylated sec-
ondary antibody (Vector Laboratories, Burlingame CA). 
Bound secondary antibody was detected using the Vectastain 
ABC kit (Vector Laboratories) and Zymed AEC Red kit 
(Zymed, San Francisco CA). A light hematoxylin counter-
stain was used to identify nuclei using Hematoxylin QS 
(Vector Laboratories). Images were taken on a Nikon Eclipse 
800 microscope (Nikon Instruments Inc., Huntley, IL) using 
identical camera settings. 
  Measurement of Skin Dermal and Collagen Bundle 
Thickness: Six m sections of paraffin-embedded skin tis-
sue were stained with hematoxylin and eosin (H & E). Im-
ages were taken on a Nikon Eclipse 800 microscope. The 
thickness of the dermis and of individual collagen bundles 
was measured using Microsuite™ Software (Olympus 
America Inc.) as we previously described [11]. Thickness 
was measured in 5 random fields in each sample. Data are 
shown in arbitrary units. 
 Statistical  Analysis:  Dermal and collagen bundle thick-
ness were analyzed using the Mann-Whitney U test. 
RESULTS 
Increased IGFBP-5 Expression in Skin Tissues of Pa-
tients with Systemic Sclerosis 
  We had previously shown that primary fibroblasts from 
skin punch biopsies of patients with SSc express signifi-
cantly greater IGFBP-5 than healthy donor fibroblasts [9]. 
Furthermore, fibroblasts from the clinically affected skin of 
patients with SSc secrete and deposit into their extracellular 
matrix significantly more IGFBP-5 compared to fibroblasts 
from the patients’ clinically unaffected skin [11]. To deter-
mine whether increased IGFBP-5 expression in vitro paral-
lels expression in vivo, IGFBP-5 levels in skin tissue from 
the clinically affected and unaffected skin of two SSc pa-
tients and those of two healthy controls were examined by 
IHC. Fig. (1) shows that IGFBP-5 protein levels are noticea-
bly increased in SSc affected skin compared to SSc unaf-
fected and healthy donor skin. IGFBP-5 was mainly ex-
pressed in epithelial cells, dermal fibroblasts and endothelial 
cells. These results extend our previous findings on in-
creased IGFBP-5 and demonstrate that the increased produc-
tion of IGFBP-5 in vitro by SSc fibroblasts reflects the aber-
rant expression in vivo.
Expression of IGFBP-5 in Human Skin Explants Paral-
lels Expression and Distribution of the Protein in SSc 
Skin 
  Human skin explants were injected intradermally with 
control adenovirus (cAd), or adenovirus expressing IGFBP-5 
(Ad5). One and two weeks post-injection, skin explants were 
fixed and embedded in paraffin. Histological examination of 
sections stained with hematoxylin and eosin revealed no 
morphological changes by at least two weeks. Electron mi-
croscopy confirmed these findings (data not shown). We 
previously reported that IGFBP-5 is increased in dermal fi-
broblasts from patients with SSc [9, 11]. To determine 
whether adenovirally encoded IGFBP-5 results in expression 
levels comparable to those observed in SSc skin, Ad-treated 
human skin explants and SSc skin sections were examined 
by IHC using anti-IGFBP-5 antibody. Fig. (2) shows that 
adenoviral expression of IGFBP-5 in human skin explants ex
vivo results in expression intensity and patterns comparable 
to those observed in SSc patient skin shown in Fig. (1). 
Fig. (1). Increased IGFBP-5 expression in affected SSc skin. 
IGFBP-5 levels in skin tissues from the affected and unaffected 
skin of a patient with SSc and a healthy donor were examined using 
IHC. Immunoperoxidase, 400x. 
Efficient Expression of IGFBP-5 in Human Skin Ex-
plants Results in Increased Dermal Thickness 
  To determine whether IGFBP-5 exerts pro-fibrotic ef-
fects ex vivo in human skin, skin tissues from four different 
donors were injected intradermally with Ad expressing 
IGFBP-3 (Ad3), IGFBP-5 (Ad5) or no cDNA (cAd). Skin 
tissue was harvested one week post adenoviral administra-
tion and sections were stained with hematoxylin and eosin. 
Fig. (3A) shows increased dermal thickness of human skin 
expressing IGFBP-5, whereas IGFBP-3 induced modest 
thickening of the skin. The increase in dermal thickness in-
duced by IGFBP-3 and IGFBP-5 was statistically significant 
(Fig. 3B). Data shown are representative of four independent 
experiments. Furthermore, IGFBP-3 and IGFBP-5 induced 
increase in dermal thickness is maintained for two weeks 
(Fig. 4). Two weeks post adenoviral injection, IGFBP-5 ex-
pression resulted in deposition of dermal collagen that was 
uniformly stained with eosin (Fig. 4). 
Increased Expression of IGFBP-5 in Human Skin Ex-
plants Results in Increased Thickness of Individual Col-
lagen Bundles 
  In addition to measuring dermal thickness, we assessed 
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ness of individual collagen bundles in the dermal layer. 
IGFBP-3 and IGFBP-5 expression resulted in significantly 
increased collagen bundle thickness and IGFBP-5 resulted in 
strong staining of collagen bundles with eosin as shown in  
Fig. (5). The increase in dermal and collagen bundle thick-
ness by the pattern of eosin staining were similar if not iden-
tical to those changes observed in the skin of patients with 
SSc. 
Fig. (2). IGFBP-5 is detected in human skin explants injected intradermally with Ad expressing IGFBP-5. IGFBP-5 expression was exam-
ined by IHC one week post-adenoviral administration. Immunoperoxidase, 400x. 
Fig. (3). IGFBP-5 expression increases dermal thickness. Human skin explants were injected with control Ad (cAd), Ad expressing IGFBP-3 
(Ad3) or Ad expressing IGFBP-5 (Ad5). Dermal thickness was assessed one week post-injection. (A) Expression of IGFBP-5 and to a lesser 
extent IGFBP-3 results in increased dermal thickness. H&E, 40x. (B) Graphical presentation of dermal thickness. * p < 0.02; ** p < 0.04. 
Data represent four independent experiments using human skin explants from four donors. 20    The Open Rheumatology Journal, 2008, Volume 2  Yasuoka et al. 
Increased Expression of IGFBP-4 Does Not Alter Dermal 
or Collagen Bundle Thickness 
  Our previous findings demonstrated that both IGFBP-3 
and IGFBP-5 trigger a fibrotic phenotype in vitro when ap-
plied to primary human fibroblasts [10]. In vivo, IGFBP-5 but 
not IGFBP-3, induced dermal fibrosis in mice [11]. The dif-
ferential effects of IGFBP-3 in human fibroblasts versus 
mouse skin may be due to the fact that human rather than 
Fig. (4). IGFBP-5, and to a lesser extent, IGFBP-3, increase dermal thickness one and two weeks post injection. Human skin explants were
injected with cAd, Ad3 or Ad5. H & E, 40X. 
Fig. (5). IGFBP-5 and IGFBP-3 expression increases collagen bundle thickness. Human skin explants were treated as in figure 3. The thick-
ness of individual collagen bundles was measured. (A) IGFBP-3 and IGFBP-5 expression results in increased thickness of individual colla-
gen bundles. (B) Graphical presentation of data presented in A. * p < 0.02. Data represent four independent experiments using skin explants 
from four different donors. H & E, 800X. IGFBP-5 Induces Fibrosis in Human Skin  The Open Rheumatology Journal, 2008, Volume 2    21
mouse IGFBP-3 was expressed adenovirally, and IGFBP-3 
may exert species-specific effects on the matrix. To determine 
if the induction of fibrosis is a general effect of IGFBPs or a 
function specific to IGFBP-3 and IGFBP-5, the assays were 
repeated with skin samples injected with cAd, Ad3, Ad5, and 
an adenovirus expressing IGFBP-4 (Ad4) as a related protein 
control. Fig. (6) shows that IGFBP-4, unlike IGFBP-3 and 
IGFBP-5, does not modulate dermal or collagen bundle thick-
ness of human skin explants. 
DISCUSSION 
  Studies have shown that percutaneous permeation of 
molecules differs in human and rodent skin [13]. Human skin 
from cosmetic surgery and amputations has been used to as-
sess the transdermal absorption of molecules and its permea-
tion and exerts similar properties to those of pig skin whereas 
permeation rates of rodent skin are much greater [13]. Human 
skin explants have been in use as an ex vivo organ culture 
model for a few different applications including the expression 
of DNA [14], the application of inhibitors to metalloprotein-
ases and other proteinases [15], and treatment with cytokines 
and growth factors such as IFN- [16]. 
  Recently, the use of human skin explants for evaluating the 
effect of potential therapeutic agents has been reported. In an 
attempt to interfere with the fibrotic process, Nath et al. re-
cently reported using antisense oligonucleotides to reduce 
Collagen Type I expression ex vivo in a skin organ culture 
model that was maintained for 7 days [17]. To extend the ap-
plication of human skin explants to in vivo gene therapy, Lip-
pin et al. obtained skin explants from patients with chronic 
renal failure and anemia, injected them with an adenovirus 
expressing human erythropoietin, and reimplanted them into 
the patients [18]. Increased circulating erythropoietin levels 
were observed for 14 days and correlated with a rise in reticu-
locyte count. Although anti-erythropoietin antibodies were 
detected 3 months following implantation, this approach sug-
gests that use of an ex vivo skin organ culture model can be 
extended to the clinical setting in diseases amenable to gene 
therapy. 
  Although numerous reports have focused on the therapeu-
tic applications of human skin ex vivo, our findings suggest 
that a) human skin explants are valuable as a model to assess 
the effects of fibrotic factors and b) expression of factors such 
as IGFBP-5, which trigger a fibrotic phenotype in vitro in 
primary human fibroblasts and in vivo in mouse skin and lung 
tissues [10-12], induces fibrosis ex vivo in a skin organ culture 
model for at least two weeks. Use of skin explants obviates the 
need for rodent models and renders all findings directly appli-
cable to human diseases such as SSc. 
  Our findings demonstrate that a) IGFBP-4 does not exert 
pro-fibrotic effects in human skin, and b) that IGFBP-3 and 
IGFBP-5 are pro-fibrotic ex vivo, although the effects of 
IGFBP-3 are more modest than those of IGFBP-5 suggesting 
that IGFBP-5 is a potent pro-fibrotic factor. Thus, IGFBP-3, -
4, and –5 exert different effects in the human skin organ cul-
ture model. Both IGFBP-3 and IGFBP-5 induce dermal fibro-
Fig. (6). IGFBP-4 does not alter the thickness of the dermis or the collagen bundles. Human skin explants were treated as in Fig. (3) except that 
skin explants were injected with control cAd, Ad3, Ad5, or Ad expressing IGFBP-4 (Ad4). (A) Dermal thickness was measured in skin tissues 
one week post-injection. (B) Collagen bundle thickness was measured in skin tissues one week post-injection. * p < 0.02; ** p < 0.03 *** p< 
0.04. Panel A: H & E, 20X; Panel B: H & E, 800X. 22    The Open Rheumatology Journal, 2008, Volume 2  Yasuoka et al. 
sis with IGFBP-5 exerting a more drastic phenotype than 
IGFBP-3. In contrast, IGFBP-4 expression did not alter der-
mal or collagen bundle thickness. These three IGFBPs share 
features that are common to the IGFBP family of proteins: 
they have conserved N-terminal and C-terminal domains that 
contain 12 and 6 conserved cysteine residues, respectively. 
They bind IGF-I with high affinity and modulate its action, 
either potentiating or inhibiting it [7, 8]. IGFBPs also exhibit 
important differences. They can exert both IGF-I-dependent 
and –independent effects and differentially regulate cellular 
functions such as apoptosis of breast epithelial cells [19]. 
IGFBP-3 and IGFBP-5 are more structurally similar to each 
other than to IGFBP-4, a smaller IGFBP that has been shown 
to inhibit IGF actions [20]. Such differences may be responsi-
ble for the different effects of IGFBP’s in the development of 
dermal fibrosis. 
  We have previously shown that both IGFBP-3 and IGFBP-
5 induce a fibrotic phenotype in vitro defined as increased 
collagen and fibronectin production and deposition in the 
ECM of primary human fibroblasts [10]. However, overex-
pression of human IGFBP-3 in mouse skin, unlike IGFBP-5, 
did not induce fibrosis [11]. In view of our current findings 
that both IGFBP-3 and IGFBP-5 induce fibrosis of human 
skin, it is likely that the inability of human IGFBP-3 to induce 
fibrosis in rodent skin is due to species-specific activities. 
Since IGFBP-5 is the most conserved of the IGFBPs, human 
IGFBP-5 was able to exert similar effects in both human and 
mouse skin. It is also conceivable that in our human skin ex-
plant model, fibrosis in response to IGFBP-3 and IGFBP-5 
develops if circulating molecules that can counteract the ef-
fects of these IGFBPs are not available. Future directions will 
address this possibility by maintaining the explants in the 
presence and absence of autologous serum and or peripheral 
blood mononuclear cells. 
  Ideally, once fibrosis in response to IGFBP-5 or other fac-
tors is established ex vivo, the explants can be treated with 
agents specific to the fibrotic factors of interest for a targeted 
therapeutic approach. Thus, the ex vivo human skin model is 
valuable for assessing the fibrotic activity of molecules of 
interest as well as evaluating the efficacy of anti-fibrotic 
therapies in a milieu that renders the findings directly applica-
ble to human disease. 
CONCLUSION 
  In conclusion, our findings demonstrate that skin explants 
can serve as a suitable ex vivo organ model to assess the role 
of IGFBP-3 and IGFBP-5 in the development of dermal fibro-
sis. Adenoviral expression of IGFBP-5 administered intrader-
mally results in IGFBP-5 expression levels and distribution 
comparable to those seen in SSc patient skin. Furthermore, 
IGFBP-5, and to a lesser extent IGFBP-3, trigger fibrosis ex
vivo in a human skin organ culture model. Thus, human skin 
explants are a suitable model to address the role of pathogenic 
molecules in the development of fibrosis and to assess the role 
of these molecules and potentially therapeutic factors in hu-
man disease. 
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